Citigroup Maintains Buy on Macrogenics, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on Macrogenics (NASDAQ:MGNX) and increased the price target from $13 to $25.

March 11, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Macrogenics and raised the price target from $13 to $25.
The upgrade in the price target by a significant margin from $13 to $25 by Citigroup, a major financial institution, is a strong positive signal to the market. This action suggests a bullish outlook on Macrogenics by the analyst, which could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100